Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLM NASDAQ:EVFM NASDAQ:ONCO NASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$6.19+7.7%$5.77$3.66▼$35.98$6.34M0.936,733 shs7,531 shsEVFMEvofem Biosciences$0.01+7.2%$0.01$0.01▼$0.02$1.23M-1.11408,726 shs942,409 shsONCOOnconetix$2.75-1.1%$3.40$2.61▼$552.50$4.30M3.3653,299 shs34,405 shsREVBRevelation Biosciences$2.47+6.0%$2.67$2.11▼$60.48$3.96M-0.04136,905 shs12.92 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics+5.18%+47.91%+7.58%-10.55%-53.56%EVFMEvofem Biosciences+7.22%+9.47%+15.56%+4.00%+10.64%ONCOOnconetix-1.08%-6.46%-3.17%-56.34%-99.33%REVBRevelation Biosciences+6.01%-9.52%+3.78%+2.28%-93.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$6.19+7.7%$5.77$3.66▼$35.98$6.34M0.936,733 shs7,531 shsEVFMEvofem Biosciences$0.01+7.2%$0.01$0.01▼$0.02$1.23M-1.11408,726 shs942,409 shsONCOOnconetix$2.75-1.1%$3.40$2.61▼$552.50$4.30M3.3653,299 shs34,405 shsREVBRevelation Biosciences$2.47+6.0%$2.67$2.11▼$60.48$3.96M-0.04136,905 shs12.92 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics+5.18%+47.91%+7.58%-10.55%-53.56%EVFMEvofem Biosciences+7.22%+9.47%+15.56%+4.00%+10.64%ONCOOnconetix-1.08%-6.46%-3.17%-56.34%-99.33%REVBRevelation Biosciences+6.01%-9.52%+3.78%+2.28%-93.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 0.00N/AN/AN/AEVFMEvofem Biosciences 0.00N/AN/AN/AONCOOnconetix 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$1.49M4.57N/AN/A$4.48 per share1.38EVFMEvofem Biosciences$11.39M0.11N/AN/A($2.64) per share0.00ONCOOnconetix$2.52M1.69N/AN/A$11.22 per share0.25REVBRevelation BiosciencesN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$53.86MN/A0.00∞N/AN/AN/AN/AN/AEVFMEvofem Biosciences$52.98M-$0.07N/A∞N/A-46.42%-91.97%-61.93%N/AONCOOnconetix-$58.69MN/A0.00∞N/A-3,327.03%-192.74%-89.55%N/AREVBRevelation Biosciences-$15.04M-$68.61N/AN/AN/AN/A-240.27%-148.95%11/14/2025 (Estimated)Latest EVFM, ONCO, APLM, and REVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ONCOOnconetixN/A-$4.05N/A-$4.76N/A$0.11 million8/7/2025Q2 2025REVBRevelation Biosciences-$4.46-$7.01-$2.55-$7.01N/AN/A6/12/2025Q1 2025ONCOOnconetixN/A$21.25N/A-$0.53N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A1.391.39EVFMEvofem BiosciencesN/A0.110.09ONCOOnconetixN/A0.070.06REVBRevelation BiosciencesN/A3.423.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%EVFMEvofem Biosciences0.22%ONCOOnconetix23.89%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/AEVFMEvofem Biosciences0.01%ONCOOnconetix3.10%REVBRevelation Biosciences2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics451.10 millionN/ANot OptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableONCOOnconetix121.55 million1.50 millionN/AREVBRevelation Biosciences101.70 million1.66 millionNot OptionableEVFM, ONCO, APLM, and REVB HeadlinesRecent News About These CompaniesRevelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical DataSeptember 10 at 7:20 AM | accessnewswire.comAReminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line DataSeptember 9 at 4:55 PM | accessnewswire.comARevelation Biosciences announces topline results from PRIME studySeptember 9 at 11:46 AM | msn.comRevelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical StudySeptember 9 at 8:00 AM | accessnewswire.comARevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025August 8, 2025 | businesswire.comRevelation Biosciences Inc. Completes Dosing of Patients in PRIME StudyJuly 16, 2025 | businesswire.comRevelation Biosciences to implement 1-for-3 reverse stock splitJuly 2, 2025 | investing.comRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - MorningstarJuly 2, 2025 | morningstar.comMRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025July 1, 2025 | businesswire.comRevelation Biosciences Inc News (REVB) - Investing.comJune 24, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 31, 2025 | finance.yahoo.comRevelation Biosciences sets terms for $4 million public offeringMay 30, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 29, 2025 | insidermonkey.comRevelation Biosciences, Inc. Announces Closing of $4 Million Public OfferingMay 29, 2025 | businesswire.comRevelation Biosciences, Inc. Announces Pricing of $4 Million Public OfferingMay 29, 2025 | finance.yahoo.comRevelation Biosciences board member steps down amid new focusMay 25, 2025 | uk.investing.comRevelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of DirectorsMay 23, 2025 | businesswire.comREVB On Track and Exploring New MarketsMay 9, 2025 | msn.comRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, ...May 8, 2025 | gurufocus.comRevelation Biosciences to Develop Gemini for Infection in Severe Burn PatientsApril 29, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVFM, ONCO, APLM, and REVB Company DescriptionsApollomics NASDAQ:APLM$6.19 +0.44 (+7.65%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$6.18 -0.01 (-0.08%) As of 09/10/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Evofem Biosciences NASDAQ:EVFM$0.01 +0.00 (+7.22%) As of 09/10/2025 03:45 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Onconetix NASDAQ:ONCO$2.75 -0.03 (-1.08%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$2.82 +0.06 (+2.36%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Revelation Biosciences NASDAQ:REVB$2.47 +0.14 (+6.01%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$2.31 -0.17 (-6.68%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
